Skip to: Content
Skip to: Site Navigation
Skip to: Search
TUESDAY, NOVEMBER 24, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Effexor

Effexor stories: 2 news summaries

Feds OK Wyeth's New Antidepressant

Faced with generic threats to its popular Effexor XR, company banking on Pristiq

Feb 29, 08 7:41 PM CST
(Newser) - Antidepressant Effexor XR will soon lose patent protection, and maker Wyeth is hoping Pristiq, the successor drug approved today by the FDA, will soften the financial blow. Higher-ups at the company gush over Pristiq's advantages, including zero acclimation time and no liver interaction, and hope that sales will offset losses... More »

MORE ABOUT:
stock market • FDA • antidepressant • Wyeth • metabolism • Effexor • patent expiration • Pristiq • metabolite

Antidepressant Studies Distort Drugs' Usefulness

New study says negative reports often go unpublished

Jan 16, 08 9:37 PM CST
(Newser) - Roughly half of the medical studies involving antidepressants that found little or no effect on patients have gone unpublished or had their findings mischaracterized as positive, a new study reveals. The emphasis on publishing only studies with glowing reviews gives patients and doctors a false sense of the effectiveness of... More »

MORE ABOUT:
FDA • antidepressant • pharmaceutical companies • Pfizer • New England Journal of Medicine • patients • doctor • Zoloft • Wyeth • Effexor

2 Stories


from our news partners